



Programme

Accelerating the TB vaccine pipeline – towards Horizon Europe

27 January – 29 January 2020

Hotel Eurotel Victoria

Les Diablerets

Switzerland



BILL & MELINDA
GATES *foundation*



Monday 27 January 2020

(Eurotel Victoria)

- 12.30 – 14.00 *Buffet lunch (restaurant Eurotel)*
- 15.00 – 18.00 - TBVI R&D partner meetings
- 15.00 – 16.30 - From TBVAC2020 to Horizon Europe
- WP 5 meeting – Tom Ottenhoff (LUMC) - room Isenau
- 16.30 – 17.00 *Break*
- 17.00 – 18.30 - R&I group - room Diablerets *(Only for members of the R&I group and invited guests)*
- 19.30 *Dinner* *(Restaurant Eurotel)*



BILL & MELINDA
GATES foundation



Tuesday 28 January 2020

(Maison des Congrès)

08.15 – 08.30 Welcome and introduction ([Nick Drager, TBVI, the Netherlands](#))

Progress in TB vaccine clinical product development

(Chair: Paul Henri Lambert, TBVI, the Netherlands)

08.30 – 08.45 M72 - ([Francois Roman, GSK, Belgium](#))

08.45 – 09.00 VPM1002 – “A pivotal multicenter phase III clinical trial - ([Sina Brueckner, VPM, Germany](#))

09.00 – 09.15 MTBVAC - “clinical development towards a new TB vaccine” - ([Ingrid Murillo, BioFabri, Spain](#))

09.15 – 09.30 H56 – “Prevention of recurrence of TB: a phase II double-blind, randomised placebo-controlled trial” - (Alvaro Borges, SSI, Denmark)

09.30 – 09.45 RUTI - “Update on RUTI clinical development” - (Père-Joan Cardona, Archivel, Spain)

09.45 – 10.00 ID93 - (Rhea Coler, IDRI, United States)

10.00 – 10.30 *Coffee break*

Rational selection and progression of TB vaccine candidates

(Chair: Gerald Voss, TBVI, the Netherlands)

10.30 – 10.50 TB Vaccine Development Pathway - ([Georges Thiry and Danielle Roordink, TBVI, Netherlands](#))

10.50 – 11.10 Preclinical candidate selection in TBVAC2020 - ([Ann Rawkins, PHE, United Kingdom](#))

11.10 – 11.30 Portfolio assessment process - (Brij Patel, TBVI, the Netherlands)

11.30 – 12.30 Pathways to impact - (*Panel* [Johan Vekemans, WHO, Switzerland](#); [Frank Cobelens, AIGHD, the Netherlands](#); Richard White, LSHTM, United Kingdom; [René Coppens, TBVI, Netherlands](#))

12.30 – 13.30 *Lunch* (Restaurant Eurotel)



Tuesday 28 January 2020 - afternoon

(Maison des Congrès)

14.00 – 18.00 **Current considerations in TB vaccine development**

(Moderated workshop chairs: Beatrice de Vos, TBVI, the Netherlands;
Hazel Dockrell, LSHTM, United Kingdom)

14.00 – 15.00 Emerging immune correlates and biomarkers

(Panel: Tom Ottenhoff, LUMC, the Netherlands; Babak Javid, TUSM, China; Hazel Dockrell, LSHTM, United Kingdom; Amita Gupta, RePORT, United States)

15.00– 16.00 Clinical development, experimental medicine and novel clinical trial designs

(Panel: Ann Ginsberg, BMGF, United States; Michelle Tameris, SATVI, South Africa; Dereck Tait, IAVI, United States; Bernard Fritzell, TBVI, the Netherlands; Helen McShane, UOXF, United Kingdom)

16.00-16.30 *Coffee break*

16.30– 17.30 Whole cell vaccines (Panel: Roland Brosch, IP, France; Olivier Neyrolles, CNRS, France; Sally Sharpe, PHE United Kingdom; Pere-Joan Cardona, IGTP, Spain; Daria Bottai, UNIFI, Italy)

17.30 – 18.00 Discussion of workshop conclusions (session chairs)

19.00 *Dinner (restaurant Eurotel)*



Wednesday 29 January 2020 (Maison des Congrès)

08.30 – 12.00 **Discovery and translation into lead candidates**

(Chair: Willem Hanekom, AHRI, South Africa)

Immunological mechanisms of protection

08.30 – 08.45 “Mycobacterial Lipids as Vaccine Antigens- What have we achieved- and what not?”
[Steffen Stenger, \(UKU, Germany\)](#)

08.45 – 09.00 “Functional assays contribute mechanistic insights into mycobacterial growth control” -
Simone Joosten, (LUMC, the Netherlands)

09.00 – 09.15 “A Next Generation Subunit Vaccine for Co-administration with BCG” - Joshua Woodworth,
(SSI, Denmark)

09.15 – 09.30 “From mouse to monkey: progress and challenges in mucosal TB vaccine testing” - Rajko
Reljic, (SGUL, United Kingdom)

Progress in preclinical models

09.30 – 09.45 “Animal models in TB vaccine development: report of a NIH/BMGF meeting in Sept. 2019” -
[Willem Hanekom, \(AHRI, South Africa\)](#)

09.45 – 10.00 “Distinctive adaptive and trained innate responses after protective mucosal BCG or MTBVAC
vaccination in NHP” - Frank Verreck, (BPRC, the Netherlands)

10.00 – 10.15 “An ultra-low dose Mtb infection model” - [Kevin Urdahl, \(SC, United States\)](#)

10.15 – 10.30 “Guinea pig models for Head to head TB vaccine evaluations” Simon Clarke, (PHE, United
Kingdom)

10.30 – 11.00 *Coffee break*

Innovation in vaccine technologies and modelling

11.00 – 11.15 “The Impact of STriTuVaD computational platform on TB vaccine pipeline: improvements and
future implications” - [Francesco Pappalardo, \(UniCt, Italy\)](#)

11.15 – 11.30 “Use of statistical modeling and simulation to drive efficient Phase 3 trial design” - Robin Mogg,
(GMRI, United States)

11.30 – 11.45 “Mathematical modelling to estimate the epidemiologic impact, cost- effectiveness and budget
impact of novel tuberculosis vaccines on multi-drug resistant tuberculosis” - Chathika
Weerasuriya, (LSHTM, United Kingdom)

11.45 – 12.00 “Human Multi-Organ-Chip-based disease modelling: progress and challenges” - [Reyk Horland,
\(TissUse, Germany\)](#)

12.00 – 13.00 *Lunch (restaurant Eurotel)*



Wednesday 29 January 2020 afternoon

(Maison des Congrès)

13.15 – 15.15 **Current and future global TB vaccine R&D to maintain and diversify the pipeline**

(Plenary chair: Hannu Laang, GTBVP)

13.15 – 13.30 TBVAC2020 final results, ([Danielle Roordink, TBVI, the Netherlands](#))

13.30 – 13.45 NIH IMPAc-TB projects, ([Rhea Coler, IDRI; Kevin Urdahl, SC, United States](#))

13.45 – 14.00 Update on GMRI activities, (Alex Schmidt, GMRI, United States)

14.00 – 14.15 CTVD discovery roadmap, (Anne Kasmar, BMGF, United States)

14.15 – 14.30 European TB vaccine priorities for Horizon Europe, (Hannu Laang, EC, Belgium)

14.30 – 14.45 Opportunities for vertical and horizontal collaboration, (Dereck Tait, IAVI, South Africa;
[Ole Olesen, EVI, Germany](#))

14.45 – 15.00 Overall conclusions (session chair)

15.00 – 15.15 **Closure**

(Nick Drager, TBVI, the Netherlands)

[Olivier Neyrolles, France](#)

15.15 – 16.00 *Coffee available in the foyer of the Eurotel*

15.30 – 19.00 **Side meetings**

15.30 – 17.20 Progress in EDCTP-funded clinical development (room Diablerets) (*Only for invited guests*)

15.30 – 16.30 R&I group meeting to discuss conclusion from conference (Room Isenau) (*Only for R&I members or invited guests*)

17.00 – 19.00 GTBVP meeting – (room Villar) (*Only for GTBVP members and on invitation*)

17.30 – 19.00 P&CDT meeting – (room Diablerets) (*Only for P&CDT members*)

19.00 *Dinner (restaurant Eurotel)*



Eurotel Victoria

Les Diablerets
Fam. Stéphane et Alexandra Wartner
Chemin du Vernex
1865 Les Diablerets
Switzerland
Phone: +41 24 492 37 21

Accommodation should be arranged via registration on website TBVI

Contact person TBVI:

Cora Agterdenbosch,
TBVI
Runderweg 6
8219 PK Lelystad
The Netherlands
Phone: +31 320 277550
e-mail: cora.agterdenbosch@tbvi.eu

Transportation:

Trains from/to Geneva Airport, change at Aigle.
120 minutes, schedules on <http://www.sbb.ch>



BILL & MELINDA
GATES *foundation*

